EMD Millipore Opens New Facility in Shanghai, China

  • Unique Validation and Training facility supports Biopharmaceutical customers in China
  • USD 2 million investment supports Chinese regulatory efforts to improve drug safety

BILLERICA, Mass. & SHANGHAI--(BUSINESS WIRE)-- EMD Millipore, the Life Science division of Merck KGaA of Germany, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 28,000 square foot facility will provide support, training and validation services to EMD Millipore’s biopharmaceutical customers with operations in China.

“We are responding to China’s commitment to strengthen regulatory requirements designed to ensure drug safety,” said Jean-Paul Mangeolle, Head of EMD Millipore’s Process Solutions business. “Our new Biopharmaceutical Technical Center is unique in that we can support and even train our pharmaceutical customers to meet the new Chinese and global regulations. Today we have taken a significant step not only expanding our 30 years of local offerings in China, but also to support the effort to produce safe, quality drugs in this important and fast growing region.”

Mangeolle was joined by a number of officials from the Chinese SFDA at today’s opening ceremonies as well as representatives of Peking University. Both institutions will utilize EMD Millipore’s new Technical Center for training courses specifically created for GMP training and Aseptic process manufacturing.

EMD Millipore’s Shanghai Biopharmaceutical Technical Center is located in Zhangjiang Hi-Tech Park and will support area biopharmaceutical manufacturers. The facility will allow local and regional customers to investigate, explore and optimize their upstream and downstream processes as well as environmental monitoring processes with the support of EMD Millipore’s local, regional and international experts. EMD Millipore operates similar facilities in Singapore, Japan, India, France, North America and Brazil.

Please see the electronic press kit available in our Media Room for additional background information.

About EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 68 countries and 2010 revenues of USD 2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

About Merck

All Merck Press Releases are distributed by email at the same time they become available on the Merck Website. Please go to http://www.merck.de/subscribe to register online, change your selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with total revenues of EUR 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 68 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.



CONTACT:

EMD Millipore
Karen Marinella Hall, +1 978 495 0829
[email protected]

KEYWORDS:   United States  Asia Pacific  North America  China  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.